Orris

Diabetes mellitus full in detail as I am a doctor I need to treat pt

Reading File
Finding Sources
Finding Sources
Searching PubMed

"diabetes mellitus" AND "management guidelines"

Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive data from multiple authoritative textbooks. Let me compile the full clinical reference for the treating physician.

Diabetes Mellitus - Complete Clinical Reference

Source textbooks: Goldman-Cecil Medicine 22E, Goodman & Gilman's Pharmacology, Washington Manual of Medical Therapeutics, Mulholland & Greenfield's Surgery, Creasy & Resnik's Maternal-Fetal Medicine, Katzung Pharmacology

1. CLASSIFICATION (ADA Framework)

  1. Type 1 DM (T1DM): Autoimmune destruction of pancreatic beta cells → absolute insulin deficiency. Accounts for 5-10% of all DM. HLA-associated (DR3, DR4 most common).
  2. Type 2 DM (T2DM): Progressive loss of beta-cell insulin secretion, frequently on a background of insulin resistance. >90% of all DM cases.
  3. Gestational DM (GDM): Diagnosed in the 2nd-3rd trimester; resolves postpartum in most but increases lifetime T2DM risk.
  4. Other specific types:
  • MODY (maturity-onset diabetes of the young): autosomal dominant; at least 11 gene mutations; MODY2 = glucokinase mutation; MODY3 = HNF-1α mutation
  • Pancreatic disease: pancreatitis, cystic fibrosis, hemochromatosis (Type 3c DM)
  • Drug-induced: glucocorticoids, antipsychotics, checkpoint inhibitors, pentamidine, diazoxide, interferons

2. EPIDEMIOLOGY

  • ~34 million Americans affected (10.5% of population)
  • Prevalence highest in American Indians/Alaska Natives (14.5%), Hispanic (12.5%), non-Hispanic Black (11.7%)
  • T1DM: 1 in 400-500 children; mean onset early teenage years, but possible at any age
  • T2DM: lifetime risk 40% with one affected parent, 70% if both parents affected; monozygotic twin concordance 70% vs dizygotic 20-30%
  • GDM: ~6% of pregnancies in the US (range 1-25% by ethnicity/criteria)

3. PATHOPHYSIOLOGY

Type 1 DM

  • Primary autoimmune destruction of beta cells; proinsulin is the most likely autoantigen
  • Genetic susceptibility: HLA region (DR3-DQ2, DR4-DQ8 haplotypes) plus >60 associated loci
  • Environmental triggers: enteroviruses strongly implicated
  • Autoantibodies: anti-GAD65, anti-IA-2, anti-insulin, anti-ZnT8 (zinc transporter 8)
  • Insulitis (lymphocytic infiltration of islets) is the pathological hallmark
  • At clinical presentation, only 10-20% of original beta-cell mass remains
  • Concordance in identical twins <100%, indicating environmental contribution

Type 2 DM

  • Initial abnormality: peripheral insulin resistance (predominantly in muscle, fat, and liver)
  • Compensatory hyperinsulinemia maintains normoglycemia initially
  • Progressive beta-cell exhaustion → hyperglycemia
  • Risk factors (Table 210-5, Goldman-Cecil):
  • Age ≥45, obesity (BMI ≥30 or >23 in Asians), sedentary lifestyle
  • First-degree relative with DM
  • Prior GDM or baby >4 kg
  • HDL <35 mg/dL or TG >250 mg/dL
  • PCOS, acanthosis nigricans, NAFLD
  • Hypertension, antipsychotic therapy, sleep disorders (OSA, shift work)
  • Long-term glucocorticoid use

4. DIAGNOSTIC CRITERIA

TestDiabetesPrediabetes
Fasting plasma glucose≥126 mg/dL (7.0 mmol/L)100-125 mg/dL (IFG)
2-h glucose (75g OGTT)≥200 mg/dL (11.1 mmol/L)140-199 mg/dL (IGT)
HbA1c≥6.5% (48 mmol/mol)5.7-6.4%
Random plasma glucose + symptoms≥200 mg/dL-
Note: Requires confirmation on a second occasion unless unequivocal hyperglycemia with symptoms or random glucose ≥200.
Screening recommendations:
  • All adults with BMI ≥30 (or >23 in Asians) + any risk factor
  • Start age 45, repeat every 3 years minimum
  • Prediabetes (HbA1c ≥5.7%, IGT, or IFG): test annually
  • Post-GDM: test at least every 3 years

5. CLINICAL FEATURES

Classic presentation: Polyuria, polydipsia, polyphagia, unexplained weight loss, fatigue, blurred vision
T1DM: Lean patient, abrupt onset, possible DKA at presentation (13-80% globally, more common in age <5 and in low-resource settings)
T2DM: Typically obese, insidious onset, often discovered incidentally on screening; may present with complications already established
Honeymoon phase (T1DM): Brief period post-diagnosis where residual beta cells may reduce exogenous insulin requirement; does not persist

6. PHARMACOLOGIC TREATMENT

Type 1 DM - Insulin is Mandatory

Insulin dosing:
  • Usual dose: 0.4-0.7 units/kg/day for most T1DM
  • Obese/pubescent/T2DM with insulin resistance: 1-2 units/kg/day
  • Basal dose: 40-50% of total daily dose
  • Prandial dose: remainder, adjusted per carbohydrate intake + correction dose
Insulin types:
TypeExamplesOnsetPeakDuration
Rapid-actingLispro, Aspart, Glulisine5-15 min1-2 h3-5 h
Short-actingRegular30-60 min2-4 h6-8 h
IntermediateNPH1-3 h6-8 h12-16 h
Long-actingGlargine, Detemir1-2 hFlat20-24 h
Ultra-longDegludec30-90 minFlat>42 h
Preferred regimens:
  • Basal-bolus: once-daily glargine/degludec + rapid-acting before each meal (gold standard)
  • Pump (CSII): continuous subcutaneous rapid-acting insulin - most physiological
  • Twice-daily NPH + Regular: less intensive, option where cost is a concern
Adverse effects of insulin: Hypoglycemia (most important), weight gain, lipohypertrophy at injection sites (rotate sites!), allergic reactions (rare)

Type 2 DM - Stepwise Pharmacotherapy

Step 1: Metformin + lifestyle (at diagnosis)
Metformin (Biguanide) - First-line for nearly all T2DM:
  • Mechanism: reduces hepatic gluconeogenesis, enhances insulin sensitivity, possible AMPK activation/mTOR inhibition
  • HbA1c reduction: 1.0-1.5%
  • Dose: Start low (500 mg OD/BD with meals) → titrate over weeks to 1-2g BD (max 2.55 g/day)
  • Extended-release: fewer GI side effects
  • Does not cause weight gain; may cause mild weight reduction
  • No hypoglycemia as monotherapy
  • UKPDS: reduced CV disease in obese T2DM (beyond glucose effect)
  • Safe with GFR >30 mL/min/1.73m²; use caution 30-45; withhold if GFR <30
  • Monitor: renal function before starting, annually thereafter; B12 levels (20-30% reduction)
  • Hold: before IV contrast, during acute illness or surgery
  • Avoid: severe pulmonary disease, decompensated HF, severe liver disease, chronic alcohol abuse
  • GI side effects (10-25%): nausea, diarrhea, bloating - diminish with slow titration and food
  • Lactic acidosis: rare; mostly in context of tissue hypoperfusion (sepsis, MI, CHF)
Step 2: Add second agent if HbA1c target not met in 2-3 months
(Choose based on CV/renal comorbidities, side-effect profile, cost):
Drug ClassExamplesHbA1c ↓Key Features
GLP-1 RALiraglutide, Semaglutide, Dulaglutide1.0-1.5%Weight loss, CV benefit (ASCVD preferred), GI SE, weekly/daily injection
SGLT2 inhibitorsEmpagliflozin, Dapagliflozin, Canagliflozin0.7-1.0%HF benefit, nephroprotective, weight loss, UTI/genital mycosis risk; euglycemic DKA risk
DPP-4 inhibitorsSitagliptin, Saxagliptin, Alogliptin0.5-0.8%Weight neutral, safe in renal impairment, well tolerated
SulfonylureasGlibenclamide, Glipizide, Glimepiride1.0-1.5%Cheap, effective; hypoglycemia + weight gain; avoid in elderly
ThiazolidinedionesPioglitazone0.8-1.0%Insulin sensitizer; fluid retention, HF risk, fractures; avoid if HF NYHA III/IV
Alpha-glucosidase inhibitorsAcarbose0.5-0.8%Delays GI glucose absorption; GI flatulence; taken with first bite of meal
InsulinNPH, Glargine, etc.Most potentWhen HbA1c very high (>10%), symptomatic, or other agents inadequate
Current evidence-based preferences (ADA 2024):
  • Established ASCVD: Add GLP-1 RA or SGLT2 inhibitor regardless of HbA1c
  • Heart failure: SGLT2 inhibitor preferred
  • Diabetic nephropathy/CKD: SGLT2 inhibitor (eGFR-dependent; initiate if eGFR ≥20)
  • Obesity: GLP-1 RA preferred (semaglutide has greatest weight loss effect)
  • Cost constraint: Sulfonylurea or NPH insulin
Step 3: Triple therapy or insulin intensification if target not met on dual therapy after 3 months
Glycemic targets (ADA):
  • HbA1c <7% for most adults (individualise)
  • HbA1c <8% for elderly, limited life expectancy, hypoglycemia unawareness
  • Fasting glucose: 80-130 mg/dL; Postprandial <180 mg/dL
  • In-hospital (critical care): 140-180 mg/dL
  • In-hospital (non-critical): fasting <140, postprandial <180 mg/dL

7. ACUTE COMPLICATIONS

Diabetic Ketoacidosis (DKA)

Definition:
  • Plasma glucose >250 mg/dL (may be lower in euglycemic DKA)
  • Arterial pH <7.30
  • Serum bicarbonate <15 mEq/L
  • Moderate ketonemia/ketonuria
Euglycemic DKA: Blood glucose <200 mg/dL; occurs in pregnancy, SGLT2 inhibitor use, starvation
Precipitants (5 I's):
  • Infection (most common)
  • Inadequate insulin
  • Infarction (MI, stroke)
  • Inflammation (pancreatitis)
  • Initial presentation of T1DM
Clinical features:
  • Polyuria, polydipsia, weight loss, nausea, vomiting, abdominal pain
  • Kussmaul respiration (deep, labored breathing)
  • Fruity/acetone breath
  • Tachycardia, dehydration, hypotension in severe cases
  • Confusion/coma (more with HHS than DKA)
Labs:
  • Anion gap metabolic acidosis (AG >12)
  • Elevated BHB (beta-hydroxybutyrate - more reliable than nitroprusside ketone test)
  • Pseudohyponatremia: correct Na⁺ = measured Na + 1.6 × [(glucose - 100)/100]
  • Hyperkalemia at presentation (but total body K depleted - will drop with insulin)
  • WBC elevated (may be metabolic, not just infection)
  • Amylase elevated (usually non-pancreatic origin)
  • Serum ketone testing may underestimate severity (does not detect BHB)
DKA Treatment Protocol (Washington Manual):
1. Fluid replacement:
  • 0.9% normal saline: 1 L in first hour (15-20 mL/kg), then 500 mL/h x 2h, then 250 mL/h
  • Switch to 0.45% saline once hemodynamically stable if Na corrected or high-normal
  • Add D5W when blood glucose <250 mg/dL
2. Insulin:
  • Regular insulin IV infusion: 0.1 units/kg/hour (no bolus needed if K⁺ ≥3.5 mEq/L)
  • Target glucose fall: 50-75 mg/dL/hour (avoid >100 mg/dL/h - risk of cerebral edema)
  • Continue until: HCO₃ >15, anion gap closed, clinical improvement
  • Switch to SC basal insulin 2 hours before stopping IV infusion
3. Potassium:
  • K⁺ <3.5 mEq/L: Hold insulin; replace K⁺ aggressively (40 mEq/h IV) before starting insulin
  • K⁺ 3.5-5.5: Add 20-40 mEq/L to IV fluids
  • K⁺ >5.5: Hold K⁺ replacement until <5.5 with good urine output
  • Monitor K⁺ every 2-4 hours
4. Bicarbonate: Not routinely recommended. Consider only if:
  • pH <6.9, OR HCO₃ <5 mEq/L
  • Hemodynamic compromise/shock or coma
  • Severe hyperkalemia with cardiac effects
  • Dose: 50-100 mEq NaHCO₃ in 1L 0.45% saline over 30-60 min; add 10 mEq KCl
5. Phosphate/Magnesium: Not routinely given; consider if not eating or ventricular arrhythmia (Mg)
6. Monitoring: BG hourly; electrolytes every 2-4h; ABG as needed

Hyperosmolar Hyperglycemic State (HHS)

Definition:
  • Blood glucose ≥600 mg/dL (33.3 mmol/L)
  • Serum osmolality >320 mOsm/kg
  • Absent or mild ketosis (enough residual insulin to suppress lipolysis)
  • Often severe mental status change
Presentation: Typically older T2DM patients; gradual onset over days; profound dehydration; neurologic symptoms (stupor, seizures, coma) proportional to hyperosmolality; up to 10% present in frank coma
Treatment: Similar to DKA but:
  • More aggressive fluid resuscitation (up to 8-10L deficit)
  • Lower insulin rates initially (0.05 units/kg/h)
  • Correct osmolality slowly (target <3 mOsm/kg/h fall)
  • Search for precipitant (infection, MI, stroke)
  • DVT prophylaxis (hypercoagulable state)

Hypoglycemia

Classification (Goldman-Cecil):
TypeDefinition
SevereNeurocognitive impairment requiring third-party assistance
Documented symptomaticGlucose ≤70 mg/dL + symptoms; self-managed
AsymptomaticGlucose ≤70 mg/dL without symptoms (hypoglycemia unawareness)
Pseudo-hypoglycemiaSymptoms with glucose >70 mg/dL
Treatment:
  • Conscious patient: 15-20g fast-acting carbohydrate (glucose tablets, juice); repeat if glucose still <70 after 15 min
  • Confused/uncooperative: 40% dextrose gel squeezed between gum and cheek
  • Unconscious/seizure: IM glucagon (1 mg) OR IV dextrose (50 mL of 50% dextrose)
  • Sulfonylurea-induced: hospitalise (prolonged effect)

8. CHRONIC COMPLICATIONS

A. Microvascular Complications

All directly related to duration and degree of hyperglycemia; tight glycemic control (DCCT/UKPDS evidence) significantly reduces their development and progression.
Diabetic Retinopathy:
  • Classification: Non-proliferative (microaneurysms, hard exudates, cotton-wool spots, intraretinal hemorrhage) → Proliferative (neovascularization - risk of vitreous hemorrhage and traction retinal detachment)
  • Macular edema can occur at any stage
  • Screening: Annual dilated fundus exam (T1DM: from puberty or 3-5 years after diagnosis; T2DM: at diagnosis)
  • Treatment: Glycemic + BP control (ACEi/ARB), laser photocoagulation (proliferative DR/macular edema), intravitreal anti-VEGF (ranibizumab, bevacizumab), vitrectomy
  • Fenofibrate may slow DR progression (FIELD, ACCORD-Eye trials)
Diabetic Nephropathy:
  • Most common cause of ESRD in Western societies
  • 30-40% of T2DM patients develop nephropathy
  • Stages: hyperfiltration → microalbuminuria (30-300 mg/day) → macroalbuminuria (>300 mg/day) → declining GFR → ESRD
  • Pathology: Kimmelstiel-Wilson nodules (nodular glomerulosclerosis), diffuse glomerulosclerosis, afferent/efferent arteriolar hyalinosis
  • Treatment: ACEi or ARB (first-line for albuminuria), SGLT2 inhibitors (empagliflozin/dapagliflozin - nephroprotective even at reduced GFR), tight glycemia, BP <130/80, protein restriction (0.8 g/kg/day), avoid nephrotoxins
Diabetic Neuropathy:
  • Lifetime prevalence ~50%
  • Distal symmetric polyneuropathy (DPN): Most common; stocking-and-glove sensory loss; responsible for 50-75% of non-traumatic amputations
  • Screening: 10g monofilament + 128 Hz tuning fork + pinprick + temperature annually
  • Treatment of painful DPN: Pregabalin (150-300 mg/day), Gabapentin (900-3600 mg/day), Duloxetine (preferred by FDA for painful DPN), Amitriptyline (10-150 mg at bedtime), Topical capsaicin 0.075%
  • Autonomic neuropathy: Orthostatic hypotension (fludrocortisone 0.1-0.3 mg/day + compression stockings), gastroparesis (metoclopramide, erythromycin 125-500 mg QID short-term), neurogenic bladder (bethanechol, self-catheterisation), erectile dysfunction (PDE5 inhibitors), diabetic diarrhea
  • Radiculoplexopathy (Bruns-Garland syndrome): Severe proximal leg pain with weakness; usually self-limiting
  • Cranial neuropathies: CN III most common (with pupillary sparing); recovers spontaneously

B. Macrovascular Complications (Accelerated Atherosclerosis)

Diabetes is an independent CVD risk factor; risk equivalent to prior MI in some patients (Haffner data).
Cardiovascular disease:
  • 2-4x increased risk of MI and stroke
  • Silent MI more common (due to autonomic neuropathy)
  • Management: Aggressive risk factor control - statin (target LDL <70 mg/dL in high-risk), ACEi/ARB, antiplatelet therapy (aspirin if established CVD), BP <130/80
  • SGLT2 inhibitors and GLP-1 RAs have proven CV mortality benefit (EMPA-REG, LEADER, SUSTAIN-6 trials)
Peripheral arterial disease (PAD):
  • Strongly associated with DM; ankle-brachial index (ABI) <0.9 is diagnostic
  • Risk of critical limb ischemia and amputation
  • Management: smoking cessation, antiplatelet, statin, revascularization when indicated
Diabetic Foot:
  • Combination of sensory neuropathy + PAD + infection
  • Typical location: plantar surface, under metatarsal heads
  • Wagner classification (Grade 0-5) guides management
  • Treatment: debridement, offloading (total contact cast), systemic antibiotics if infected, revascularization if PAD present, amputation if bone involved or non-healing
  • Prevention: foot exam at every visit, patient education, proper footwear

9. CARDIOVASCULAR RISK MANAGEMENT (Critical for Reducing DM Mortality)

ParameterTarget
HbA1c<7% (individualise)
BP<130/80 mmHg
LDL<70 mg/dL (high CV risk); <55 mg/dL (very high risk)
TG<150 mg/dL
AspirinLow-dose if established CVD; consider for primary prevention in high CV risk
SmokingCessation mandatory
Weight5-10% loss significantly improves glycemia, BP, and lipids
Exercise≥150 min/week moderate-intensity aerobic; resistance training 2-3x/week

10. DIABETES IN SPECIAL POPULATIONS

Gestational DM:
  • Screen at 24-28 weeks (or earlier if high risk) with 50g GCT or 75g OGTT (IADPSG criteria)
  • Treatment: Medical nutrition therapy first; insulin if targets not met (metformin/glyburide used off-label)
  • Glycemic targets in pregnancy: fasting <95, 1h post-meal <140, 2h post-meal <120 mg/dL
  • Postpartum: OGTT at 4-12 weeks to screen for persistent T2DM
Elderly:
  • Relaxed HbA1c targets (7.5-8.5%) to minimize hypoglycemia
  • Avoid sulfonylureas with long half-lives; prefer DPP-4 inhibitors, GLP-1 RA
  • Falls risk from hypoglycemia is significant
Chronic Kidney Disease:
  • Metformin: safe if eGFR >30; avoid if <30
  • SGLT2 inhibitors: empagliflozin/dapagliflozin - initiate if eGFR ≥20 for renal protection
  • Sulfonylureas: avoid glibenclamide (long-acting); glipizide safer
  • Dose-adjust insulin (reduced clearance increases hypoglycemia risk)
Inpatient/Perioperative:
  • ICU target: 140-180 mg/dL
  • Non-ICU target: fasting <140, random <180 mg/dL
  • Hold SGLT2 inhibitors, metformin (contrast/NPO), GLP-1 RA in most situations
  • Insulin (basal-bolus or insulin infusion) is preferred in hospital
  • Resume outpatient regimen at discharge with education

11. PREVENTION

Lifestyle intervention (DPP trial): 5-7% weight loss + 150 min/week exercise → 58% reduction in progression from prediabetes to T2DM Metformin (500-1000 mg BD): 31% reduction in DM progression (recommended by ADA for prediabetes, especially BMI >35, age <60, or prior GDM) Acarbose: 25% risk reduction in prediabetes Liraglutide 3 mg/day: ~20% reduction in incident T2DM in obese patients with prediabetes Bariatric surgery: Most effective intervention; T2DM remission in 60-80% of obese patients

12. MONITORING TOOLS

TestFrequencyNotes
HbA1cEvery 3 months (unstable/changing therapy); every 6 months (stable)Unreliable with hemoglobinopathy, hemolysis, recent transfusion
Self-monitoring BG (SMBG)T1DM: ≥4 times/day; T2DM: as indicated
CGM (continuous glucose monitoring)T1DM standard of care; T2DM on insulinTime-in-range (70-180 mg/dL) >70% target
Urine/serum albuminAnnuallySpot urine albumin:creatinine ratio
eGFRAnnually
Fasting lipidsAt diagnosis, then annually
Dilated eye examAs above
Foot examEach visit (10g monofilament, pulses, ABI if PAD suspected)
BPEach visit
Dental examEvery 6 months
Thyroid function (T1DM)Periodically (associated autoimmune)

13. QUICK DIAGNOSTIC WORKUP AT FIRST PRESENTATION

  1. Fasting BG, random BG, HbA1c, OGTT if needed
  2. Urine ACR (albumin:creatinine ratio), eGFR/creatinine
  3. Fasting lipid profile
  4. LFTs (NAFLD screening)
  5. BP measurement
  6. Dilated fundus exam (refer ophthalmology)
  7. Foot exam (monofilament, pulses, ABI if warranted)
  8. BMI, waist circumference
  9. In T1DM: anti-GAD65, anti-IA-2, anti-insulin antibodies, C-peptide; thyroid function; coeliac screen (anti-tTG)
  10. ECG in T2DM >45 or with cardiac symptoms
Recent evidence note: A 2024 systematic review on diabetic foot infections (PMID 39165660) emphasises culture-guided antibiotics and multidisciplinary teams for DFI management. A 2026 systematic review on hyperosmolar hyperglycemic state (PMID 41587208) highlights significant variability in HHS management guidelines, recommending a more uniform evidence-based protocol.
Key References:
  • Goldman-Cecil Medicine International Edition (2-Volume Set) - Chapter 210
  • Goodman & Gilman's Pharmacological Basis of Therapeutics - Chapter 51
  • The Washington Manual of Medical Therapeutics - Chapter 23
  • Creasy & Resnik's Maternal-Fetal Medicine - Chapter 59
  • Mulholland & Greenfield's Surgery - Chapter (Metabolic)
This is a shared conversation. Sign in to Orris to start your own chat.